We aimed to present a rare case in which we detected drug-induced QTc prolongation with piperacillin/tazobactam in clinical practice.
📌 3 Key Takeaways
🎯
Objective & Hypothesis:Drug-induced QT prolongation with T wave inversion is a complex regulatory and clinical problem due to the rarity of this potentially fatal adverse incident.
📊
Key Findings & Data:A 68-year-old female patient was receiving piperacillin/tazobactam therapy for a complicated urinary tract infection.
💡
Conclusion & Impact:We aimed to present a rare case in which we detected drug-induced QTc prolongation with piperacillin/tazobactam in clinical practice.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:torsades de pointes · drug-induced long QT syndrome · piperacillin/tazobactam
Abstract
Drug-induced QT prolongation with T wave inversion is a complex regulatory and clinical problem due to the rarity of this potentially fatal adverse incident. A 68-year-old female patient was receiving piperacillin/tazobactam therapy for a complicated urinary tract infection. She has had normal ECG findings before the antibacterial therapy. After the treatment, the patient worsens due to long QT which is predisposed to torsades de pointes. As a result of the researches, it was understood that the cause of long QT was piperacillin/tazobactam. We aimed to present a rare case in which we detected drug-induced QTc prolongation with piperacillin/tazobactam in clinical practice.
DUYAN, M., GÜNLÜ, S., SARIDAŞ, A., CANDER, B., SOLAÇ, Y. (2021). A fatal side effect of piperacillin/tazobactam use: a case report.. Eurasian Journal of Critical Care, Cilt: 3 - Sayı: 3, 119–121. https://ajindex.com/articles/756069
:1. Goldenberg I, Moss AJ, Zareba W. QT interval: how to measure it and what is "normal". J Cardiovasc Electrophysiol. 2006
17(3):333-336. doi:10.1111/j.1540-8167.2006.00408.x 2. Antzelevitch C, Shimizu W. Cellular mechanisms underlying the long QT syndrome. Curr Opin Cardiol. 2002
17(1):43-51. doi:10.1097/00001573-200201000-00007 3. Woosley RL. QT Drug Lists by Risk Groups. AZ: Arizona Center for Research and Education on Therapeutics. Published 2009. Accessed September 1, 2021. http:// www.azcert.org/medical-pros/drug-lists/drug-lists.cfm 4. Katchman AN, Koerner J, Tosaka T, Woosley RL, Ebert SN. Comparative evaluation of HERG currents and QT intervals following challenge with suspected torsadogenic and nontorsadogenic drugs. J Pharmacol Exp Ther. 2006
316(3):1098-1106. doi:10.1124/jpet.105.093393 5. Poluzzi E, Raschi E, Motola D, Moretti U, De Ponti F. Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf. 2010
33(4):303-314. doi:10.2165/11531850-000000000-00000 6. Panduranga P, Al-Mukhaini M, Rajarao MP. Multi-factorial causes of torsade de pointes in a hospitalised surgical patient. Sultan Qaboos Univ Med J. 2013